COVID-19 vaccine counseling and safety assessment in children and teenagers with underlying medical conditions in China: a single center study

ABSTRACT Safety concerns about novel vaccines and necessity of COVID-19 vaccination for children, especially with underlying medical conditions, are the obstacle of COVID-19 vaccination program among pediatric population. The study was conducted to investigate the vaccine hesitancy reasons among the parents, and to monitor the adverse events of inactivated COVID-19 vaccines in children and teenagers with underlying medical conditions in China. Children with underlying medical conditions encountered to the Immunization Advisory Clinic for COVID-19 vaccine counseling were enrolled. They were given immunization recommendation and followed up at 72 h and 28 d after immunization to monitor the immunization compliance after consultation and adverse events. A total of 324 children aged 3–17 y were included. The top three primary medical conditions for counseling were allergy (33.6%), neurological diseases (31.2%) and rheumatic diseases (8.3%). COVID-19 vaccination was promptly recommended for 242 (74.7%) children. Seventy-one (65.7%) children who had allergy issues were recommend to take vaccination, which was significantly lower than that of other medical conditions (p < .05). The follow-up record showed that 180 children received 340 doses of inactivated COVID-19 vaccine after consultation. Overall, 39 (21.6%) children reported at least one adverse event within 28 d of either vaccination. No serious adverse reactions were observed. No difference of adverse effects between the first dose and the second dose of vaccination except fever. Parents’ hesitancy in COVID-19 vaccination for children with underling medical conditions are mainly due to the safety concerns. Specialist consultation is helpful to improve the vaccine uptake.

[1]  M. Ardura,et al.  An Exploration of COVID-19 Impact and Vaccine Hesitancy in Parents of Pediatric Hematopoietic Stem Cell Transplant (HCT) Recipients , 2022, Bone Marrow Transplantation.

[2]  Wei Peng,et al.  COVID‐19 vaccine take‐up rate and safety in adults with epilepsy: Data from a multicenter study in China , 2021, Epilepsia.

[3]  Weihong Lin,et al.  A Survey of Hesitancy and Response to the COVID-19 Vaccine Among Patients With Epilepsy in Northeast China , 2021, Frontiers in Neurology.

[4]  C. Agostoni,et al.  COVID-19 Vaccine Hesitancy among Parents of Children and Adolescents Living in Brazil , 2021, Vaccines.

[5]  Matthew M Davis,et al.  Parental COVID-19 vaccine hesitancy for children: vulnerability in an urban hotspot , 2021, BMC Public Health.

[6]  J. Nelson,et al.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination. , 2021, JAMA.

[7]  W. Wang,et al.  Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial , 2021, The Lancet Infectious Diseases.

[8]  H. Oshitani,et al.  Roles of Children and Adolescents in COVID-19 Transmission in the Community: A Retrospective Analysis of Nationwide Data in Japan , 2021, Frontiers in Pediatrics.

[9]  S. Ahmad,et al.  Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study , 2021, Seizure.

[10]  Changgui Li,et al.  Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial , 2021, The Lancet Infectious Diseases.

[11]  A. Sahraian,et al.  Physicians’ opinions on the necessity of COVID‐19 vaccination in patients with epilepsy , 2021, Epileptic disorders : international epilepsy journal with videotape.

[12]  Austin Waters,et al.  COVID-19 Vaccine Hesitancy Among Adolescent and Young Adult Cancer Survivors , 2021, JNCI cancer spectrum.

[13]  K. Hoffman,et al.  COVID-19 Vaccine Hesitancy and Acceptance Among Individuals With Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based Survey , 2021, JMIR public health and surveillance.

[14]  S. Vieths,et al.  EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines , 2021, Allergy.

[15]  E. Şenel,et al.  Evaluation of COVID-19 Vaccine Refusal in Parents. , 2021, The Pediatric infectious disease journal.

[16]  A. Sheikh,et al.  Vaccination and allergy: EAACI position paper, practical aspects , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[17]  P. Demoly,et al.  International Consensus (ICON): allergic reactions to vaccines , 2016, The World Allergy Organization journal.

[18]  Nicola P Klein,et al.  Risk of anaphylaxis after vaccination in children and adults. , 2016, The Journal of allergy and clinical immunology.

[19]  V. Usonis,et al.  Immunization of high-risk paediatric populations: Central European Vaccination Awareness Group recommendations , 2014, Expert review of vaccines.